Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, Univ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-04-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/evaluating-nelipepimut-s-in-the-treatment-of-breast-cancer-a-short-rep-peer-reviewed-article-BCTT |
| _version_ | 1818900107199774720 |
|---|---|
| author | Dillon PM Brenin CM Slingluff CL Jr |
| author_facet | Dillon PM Brenin CM Slingluff CL Jr |
| author_sort | Dillon PM |
| collection | DOAJ |
| description | Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, University of Virginia, Box 800716, Charlottesville, VA 22908, USATel +1-434-982-1495Fax +1-434-244-7534Email Pmd5b@hscmail.mcc.virginia.eduAbstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.Keywords: vaccine, breast cancer, HER2, peptide, human |
| first_indexed | 2024-12-19T19:58:36Z |
| format | Article |
| id | doaj.art-8f13b704edc548b7967b873fe2665815 |
| institution | Directory Open Access Journal |
| issn | 1179-1314 |
| language | English |
| last_indexed | 2024-12-19T19:58:36Z |
| publishDate | 2020-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Breast Cancer: Targets and Therapy |
| spelling | doaj.art-8f13b704edc548b7967b873fe26658152022-12-21T20:07:43ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142020-04-01Volume 12697552919Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging DataDillon PMBrenin CMSlingluff CL JrPatrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, University of Virginia, Box 800716, Charlottesville, VA 22908, USATel +1-434-982-1495Fax +1-434-244-7534Email Pmd5b@hscmail.mcc.virginia.eduAbstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.Keywords: vaccine, breast cancer, HER2, peptide, humanhttps://www.dovepress.com/evaluating-nelipepimut-s-in-the-treatment-of-breast-cancer-a-short-rep-peer-reviewed-article-BCTTvaccinebreast cancerher2peptidehuman |
| spellingShingle | Dillon PM Brenin CM Slingluff CL Jr Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data Breast Cancer: Targets and Therapy vaccine breast cancer her2 peptide human |
| title | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| title_full | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| title_fullStr | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| title_full_unstemmed | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| title_short | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| title_sort | evaluating nelipepimut s in the treatment of breast cancer a short report on the emerging data |
| topic | vaccine breast cancer her2 peptide human |
| url | https://www.dovepress.com/evaluating-nelipepimut-s-in-the-treatment-of-breast-cancer-a-short-rep-peer-reviewed-article-BCTT |
| work_keys_str_mv | AT dillonpm evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata AT brenincm evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata AT slingluffcljr evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata |